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Bladder cancer is a biologically and clinically heterogeneous disease. Traditional 
classification systems, based on pathologic grade, stage and clinical prognosis 
fail to fully explain how tumors with similar pathology exhibit diverse biological 
behavior. The introduction of transcriptomics technology has allowed us to catalog 
all of the mRNA expression patterns and DNA alterations in a given tumor thus 
expanding our understanding of human cancers. Molecular subtype profiling was 
attempted only recently in bladder cancer, with the earliest attempts dating back to 
2010. Several different molecular classification systems have emerged since. Some 
of these systems address early bladder cancer, while others focus exclusively on the 
life-threatening muscle invasive tumors. These molecular subtypes have distinct 
morphological and clinical characteristics with different therapeutic and prognostic 
implications, particularly in the era of targeted therapies and immunotherapy. 
However, molecular subtyping is not without its limitations. Despite the rapidly 
expanding evidence for important clinical implications, much work is still needed 
to establish the utility (or lack thereof) of molecular subtyping, and its application 
in daily practice.
Keywords: molecular classification, muscle invasive bladder cancer, taxonomy, 
transcriptomics, targeted therapy
1. Introduction
Bladder cancer is the most common malignant tumor involving the urinary 
tract. Histologically, bladder cancers can be urothelial carcinomas, squamous cell 
carcinomas and adenocarcinomas, out of which urothelial carcinomas constitute 
over 90% [1]. Urothelial carcinoma is derived from the specialized epithelia of the 
bladder wall. Using a well-established differentiation program, basal stem cells at 
the stromal interface self-renew and generate intermediate and superficial urothe-
lial cells to maintain and regenerate the urothelium in response to daily wear and 
tear. Bladder cancer results from the deregulation of this program. Conventionally, 
bladder cancer can be divided into non-muscle invasive bladder cancer (NMIBCs) 
and muscle invasive bladder cancers (MIBCs), based on the invasion of the 
muscularis propria. The low grade superficial NMIBCs and high grade MIBCs 
(HG MIBCs) develop along divergent molecular pathways of tumorigenesis and 
also show diverse biological behavior and molecular profile. Low grade NMIBCs 
constitute the majority of newly diagnosed bladder cancer cases, typically have a 
long protracted clinical course characterized by multiple recurrences, and require 
life-long monitoring, significantly contributing to bladder cancer morbidity. On the 
Modern Approach to Diagnosis and Treatment of Bladder Cancer
2
other hand, a large proportion of the MIBCs eventually metastasize, contributing to 
the bulk of bladder cancer mortality [2, 3].
Low grade papillary urothelial carcinomas occur due to fibroblast growth factor 
receptor 3 (FGFR3)/RAS/RAF pathway alterations, while the HG MIBCs develop 
along the TP53/RB1 mutation pathway [4, 5]. Chromosome 9 deletion occurs in the 
early phase of bladder cancer tumorigenesis. FGFR3/HRAS mutations frequently 
occur during the development of hyperplasia and low grade (Ta) carcinoma. 
Hyperplasia develops into high grade urothelial carcinoma (Ta) through the 
acquisition of CDKN2A alterations, which may progress to become T1 carcinoma 
after additional TP53/RB1 inactivation. TP53 mutations frequently occur during 
the development of urothelial dysplasia. These may develop into carcinoma in situ 
(Tis) after RB1 inactivation, which then progresses through non-muscle invasive 
infiltrating urothelial carcinomas (T1) to muscle invasive (T2) carcinoma.
Traditional classifications for bladder cancer are mainly based on pathological 
features and tumor stage. However, even with similar pathological staging and 
grading, recurrence and progression of bladder cancer shows marked heterogeneity, 
and directly affects optimal monitoring and treatment response. Only a proportion 
of cases of bladder cancer of a given grade and stage will progress to a higher stage. 
Thus the same treatment, such as, transurethral resection alone, or the administra-
tion of BCG or neoadjuvant chemotherapy may not be adequate for others. Some 
tumors are less likely to metastasise and need only local resection, while others are 
highly invasive and need radical cystectomy and/or other treatments. Currently, 
there is still no effective means to distinguish between the two. The pathological 
features of the tumor cannot fully reflect the “intrinsic characteristics” of blad-
der cancer.
With the rapid development of sequencing, mass spectrometry and other 
techniques, studies based on the ‘-omics’ technology has transformed our under-
standing of human cancers. The basic method involves cataloging the entire mRNA 
expression pattern and DNA alteration profile by sequencing, microarray and 
other technologies and then performing a cluster analysis of the different genes 
based on gene expression levels and genes involved in a given biological process. 
After performing hierarchical cluster analysis on mRNA expression profiling data, 
clusters were validated by DNA PCR and/or immunohistochemistry (IHC), DNA 
methylation profiling, miRNA or lncRNA analysis. Among the earliest applica-
tions of this approach was to define intrinsic molecular subtypes in human breast 
cancer by Perou et al., [6]. Subsequently, over the last decade, molecular subtypes 
with distinct clinical behavior, histology and response to treatment were identi-
fied in other malignancies e.g. colon cancer, gliomas, acute leukemias and so on. 
Molecular subtype profiling was applied only recently in bladder cancer, with the 
earliest attempts dating back to 2010. Several different molecular classification 
systems have emerged since, with four standing out in the MIBCs, developed by 
Lund University group [7–10], The Cancer Genome Atlas (TCGA) consortium 
[11, 12], MD Anderson Cancer Centre [13] and the University of North Carolina 
[14]. Several other studies have followed up, in an attempt to unify [15] and reach a 
consensus [16] between the classification systems. Although each group defended 
the existence of a different numbers of subtypes (n = 2–6), there was remarkable 
overall concordance among the groups (Table 1). At the highest level, all classifica-
tion systems recognized the existence of intrinsic luminal and non-luminal (basal) 
subtypes, which resembled normal luminal/intermediate and basal urothelial cells 
in gene expression profile.
For the two major types of bladder cancer, NMIBC and MIBC, molecular sub-
typing of bladder cancer can be divided into early subtyping (which included both 
NMIBC and MIBC), NMIBC subtyping and MIBC subtyping (Table 2).
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2. Early bladder cancer subtyping systems
The earliest representative studies on the molecular classification of bladder 
cancer were conducted by Sjödahl et al. at the University of Lund, initially pro-
posed in 2010 and finalized in 2012 and the tumor differentiation classification 
TCGA [12] Lund [8] MDACC [13] UNC [14] Properties
Cluster I UroA, GU Luminal Luminal FGFR mutations, papillary histology
Cluster II Infiltrated p53-like Luminal CAFs, immune cells
Cluster III SCC-like, 
UroB
Basal Basal Stem cell markers, squamous 
differentiation
Cluster IV Infiltrated p53-like Claudin-low EMTs, CAFs, immune cells
Table 1. 
Table showing overlap between the subtypes in the initial classification systems and the cardinal properties 












n = 308 Urobasal A, genomically unstable, 
infiltrated, urobasal B and squamous cell 
carcinoma-like
Baylor tumor differentiation 
classification 2012 [19]
3 subtypes





n = 400 Class1, 2 and 3
Van Kessel 2018 [21]
3 subtypes
n = 1239 EAU high risk NMIBCs classified into 










n = 83 Luminal, p53-like and basal
TCGA 2014 [12]
4 subtypes
n = 129 Clusters I, II, III and IV
TCGA 2017 [11]
5 subtypes






n = 1750 Luminal-papillary, luminal not specified, 








n = 2411 Neural-like, luminal-like, papillary-like, 
HER2-like, squamous cell carcinoma-like 
and mesenchymal-like
Table 2. 
Summary of major molecular subtyping systems, adapted from Zhu et al., 2020 [18].
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by Chan et al., of the Baylor University group, 2012 [19]. The Baylor classification 
focused on tumor biology. They proposed a KRT14/Thy-1/CD44 expressing cancer 
stem cells as the bladder cancer precursor. This cancer stem cell evolved into a par-
tially differentiated KRT5/KRT17/CD44-positive progeny, which in turn acquired 
KRT8/18 expression and eventually differentiated into luminal cells expressing 
uroplakins and KRT20. Tumors were classified into basal, intermediate and dif-
ferentiated classes based on their resemblance to normal urothelial differentiation. 
Based on the above classification, the KRT14 group (basal subtype) showed the 
poorest prognosis and were also found to be resistant to neoadjuvant cisplatin-based 
chemotherapy.
The Lund University group initially defined two intrinsic molecular subtypes 
named as MS1 and MS2 based on gene expression, genomic, and gene mutation lev-
els by whole genome comparative genomic hybridization and mutation studies [7]. 
By combining molecular and pathologic data, it was possible to divide tumors into 
grade 1 or 2 (MS1) and grade 3 (MS2) (WHO1999), and into Ta (MS1) and ≥ T2 
(MS2) stages based on the MS1 and MS2 subtypes.
Subsequently, an extensive biological interpretation of gene expression data 
identified that biological themes including immune, late cell cycle, keratin, receptor 
tyrosine kinases and FGFR3 signatures determined their data structure. Based on 
tumor histopathology, gene signatures, and status of FGFR3, PIK3CA, and TP53 
mutations, three major subtypes of UC were defined: urobasal (Uro) (further 
subdivided into MS1a, MS1b, and MS2b2.1), genomically unstable (GU) (MS2a1 
and MS2a2), and SCC-like (SCCL) (MS2b2.2) [8]. Subsequent studies also identi-
fied an “infiltrated” group in which the stromal inflammatory transcripts were 
prominently expressed. Among the urobasal tumors (MS2b2.1), a subset showed 
“progressed phenotype” with aberrant expression of basal keratins in suprabasal 
cell layers and upregulation of late cell cycle activity. These tumors were mostly 
large and invasive, and were named urobasal B to distinguish it from urobasal A 
tumors that were non-muscle invasive in almost all cases. The molecular subtypes 
thus defined, transcended pathological staging and all four subtypes (UroA, UroB, 
GU, and SCCL) were detected among T1 tumors. The initial Lund taxonomic 
studies included both NMIBC and MIBC and subsequent studies focussed predomi-
nantly on MIBC classification.
3. Molecular subtyping of early-stage bladder cancer
Variability in terminology has created a challenge in the molecular classifica-
tion of early-stage bladder cancer. Treating clinicians emphasize the dichotomous 
division of BCs into NMIBC and MIBC, and often lump all NMIBCs together when 
planning molecular studies. In contrast pathologists tend to see a stark difference 
between non-invasive tumors and invasive tumors limited to the lamina propria 
and classify accordingly.
Molecular diversity in non-invasive BC differs from that of MIBC. Non-invasive 
BC histologically includes papillary UC and flat CIS, although both may co-exist in 
the same patient. As we have discussed earlier, low-grade non-invasive papillary UC 
has a high frequency of FGFR3 mutation. LGUC progresses to HGUC and invasive 
carcinoma through the acquisition of TP53 mutations and 9p21 loss involving the 
gene encoding CDKN2A. In contrast, most CIS lesions have TP53 mutations early in 
evolution and do not acquire FGFR3 mutations [4, 5].
In the Lund system [8], majority of non-invasive UCs are urothelial-like, while 
CIS may be either urothelial-like or genomically unstable. They identified a “CIS 
signature” by utilizing a 16-gene classifier which was specifically expressed in flat 
5
Molecular Classification of Bladder Cancer
DOI: http://dx.doi.org/10.5772/intechopen.97393
CIS, as well as in early-stage invasive carcinoma with associated CIS, and a large 
proportion of MIBCs of the basal-squamous subtype. In addition, MIBCs with 
concurrent CIS had greater genomic instability compared with those without it. 
Although majority of non-invasive papillary UCs were of luminal subtype, there is 
substantial molecular diversity among cases. The most clinically relevant diversity 
was related to cell cycle regulatory genes. Tumors with greater activation of the cell 
cycle had higher rates of recurrence and progression to MIBCs.
The UROMOL study of 2016 [20] evaluated expression profiles of NMIBCs 
including non-invasive papillary UC and invasive UC limited to the lamina propria 
(stage T1). A few cases of CIS and a small group of MIBCs were also included for 
comparison. Tumors were classified into 3 subtypes based on relative expression of 
luminal and basal-squamous markers and cell cycle activity. Three subtypes were 
proposed, named as Type 1 (early cell cycle activation and higher luminal gene 
expression), Type 3 (early cell cycle activation with lower luminal gene expres-
sion) and Type 2 (late cell cycle activation). Type 2 tumors, which included the 
highest proportion of T1 samples, had the greatest propensity to progress to muscle 
invasion. On the other hand, expression of luminal genes did not significantly 
affect patient outcome. In addition, non-invasive papillary tumors also varied in 
the degree of chromosomal instability. The unstable group had tumors with higher 
proliferation, greater mutational burden, and high-grade histology.
Von Kessel et al., in 2018 [21], determined that methylation status of GATA2, 
TBX2, TBX3 and ZIC4 and mutations in FGFR3, TERT, PIK3CA, and RAS cor-
related with progression rates of NMIBC. Wild-type FGFR3 and GATA2 and TBX3 
methylation were significantly correlated with NMIBC progression. Thus, high risk 
NMIBC group was reclassified into good, moderate and poor prognostic classes 
with low, medium and high risk of progression.
However, because molecular subtyping of non–muscle-invasive bladder cancer 
has not demonstrated clear value in clinical decision making, it is not currently 
recommended to incorporate it on a routine basis, as per the ISUP recommenda-
tions published in 2020.
4. Molecular subtyping of MIBC
Much of the work on molecular subtyping of bladder cancer has been under-
taken with MIBCs in consideration and an increasing number of classification 
systems have emerged with four of them standing out (Figure 1). Although the 
subtypes within these systems are largely similar, they differ in clinically and 
biologically meaningful ways.
The UNC classification proposed by Damrauer et al. [14], used K2 consensus 
clustering, to divide tumors into basal (KRT5/6 and CD44) vs. luminal (PPARG, 
GATA3, KRT20, and UPK2) subtypes utilizing a 47 gene classifier, BASE47. The 
basal subtype showed similarities with the basal subtype of breast cancers, as 
demonstrated by applying the PAM50 signature to their dataset. In addition, like 
in breast cancers, a claudin-low subgroup was identified among basal tumors. 
The claudin-low subgroup had outcomes similar to basal tumors and was rich in 
epithelial-mesenchymal transition (EMT) signatures and tumor initiating cell 
markers. A significant enrichment in genes related to inflammatory cell infiltration 
and immune checkpoint was also seen in the basal subgroup and, more specifically, 
among the claudin-low tumors. There was no significant difference in TP53 path-
way alterations in the subtypes. The basal subtype, which was more frequent among 
females, had a high rate of RB pathway gene alterations, while the luminal subtype 
was rich in FGFR3 and TSC1mutations.
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The MDA group [13] also classified BC into basal, p53-like and luminal tumors 
similar to breast cancer. Their luminal and p53-like subtypes had similar mRNA 
profiles but wild-type p53 gene was significantly activated in the p53-like sub-
type. All three subtypes had similar frequency of p53 mutations, but the p53-ness 
contributed by increased wild-type p53 expression was thought to contribute to 
chemo-resistance in the p53-subtype. The basal subtype was enriched in squamous 
cell differentiation markers and activated p63 and was more invasive with poorer 
clinical prognosis.
The TCGA 2014 [12] subtyped MIBCs into four clusters numbered I to IV utiliz-
ing an integrated genomic analysis of chemotherapy-naive, invasive UCs by analyz-
ing for somatic mutations, DNA copy number alterations, mRNA and microRNA 
expression profile, as well as protein analysis, and DNA methylation studies. Cluster 
I predominantly exhibited papilloma phenotype and was enriched in FGFR3 muta-
tions. Both cluster I and II expressed GATA3, FOXA1, UPK3A transcription factors 
and uroplakin family of genes and were enriched in RBB2 mutations and ER beta. 
Cluster III expressed squamoid phenotype and its associated keratin expression. 
Subsequently in 2017, TCGA expanded their classification [11] into five distinct 
subtypes, diving luminal tumors into three subtypes, luminal papillary, luminal and 
luminal infiltrated. They also included a neural subtype in addition to the earlier 
described basal subtype.
4.1 Intrinsic molecular subtypes and intra-tumor heterogeneity
Intrinsic molecular subtype, a term which first used in breast carcinomas [6] 
refers to subtypes which reflect an intrinsic property of the tumor. The luminal and 
basal intrinsic subtypes reflect the property of the tumor cells to show urothelial or 
basal stem-cell-like differentiation signatures [23].
However, transcriptomic studies identified the entire genetic signature of a 
tumor, which in the case of invasive malignancies, included variable components 
of stromal and immune signatures. Thus, in addition to the two intrinsic subtypes, 
some of the subtypes defined in the various study groups were based on the 
Figure 1. 
Figure showing the similarities between the molecular subtypes in the different classification systems. Luminal 
and basal subtypes exist in all classification systems (figure adapted from Zhu et al. [18]).
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characteristics of the tumor-stroma or tumor infiltrating inflammatory cells such as 
the p53-like‘subtype [13], infiltrated subtype [8], luminal-infiltrated subtype [11] 
as examples. These non-intrinsic subtypes could be recognized as a property of the 
stroma or inflammatory cells when studies were performed later which localized 
the gene expression patterns in situ, by immunohistochemistry [10, 23, 24]. Many 
of these non-intrinsic subtypes could be resolved into luminal and basal subtypes 
based on tumor phenotype on immunohistochemistry, while others continued to 
express non-luminal, non-basal phenotype, like the double negative subtype of 
Dadhania et al., [24].
4.1.1 Intrinsic luminal subtype
At the top of the hierarchical level, MIBCs were divided into luminal-like and 
nonluminal-like classes based on the presence or absence of bimodally expressed 
urothelial differentiation signature.
About half of the MIBCs expressed this signature characterized by the expres-
sion of KRT20, UPK1–3 (uroplakin 1, 2 and 3), epithelial biomarkers (E-cadherin/
CDH1 and members of the miR-200 family), along with transcriptional regulators 
PPARG (peroxisome proliferator activated receptor-γ), GRHL2–3 (grainyhead 
like transcription factor), ELF3 and TBX2–3. Luminal MIBCs also displayed active 
Estrogen Receptor/TRIM24 pathway gene expression and were enriched with 
FOXA1, GATA3, ERBB2 and ERBB3 expressed on superficial (umbrella cells) and 
intermediate cells of the normal urothelium [7]. There was increased expression of 
fibroblast growth factor receptor-3 (FGFR3), with activating FGFR3 mutations in 
the most differentiated luminal tumors.
The luminal tumors were further sub-stratified into urothelial-like (UroA, UroB 
and UroC) and genomically unstable (GU) subtypes by the Lund University group 
[8], luminal papillary, luminal and luminal infiltrated subtypes by TCGA [11] and 
luminal papillary, luminal non-specified, and luminal unstable subtypes in the 
Consensus classification [16].
The urothelial-like tumors expressed FGFR3 and CCND1, and frequently showed 
9p21 (CDKN2A) loss. On immunohistochemistry, only the urothelial-like tumors 
retained the basal stratification seen in normal urothelium and express CK5 at least 
focally, particularly at the tumor-stroma interface [9, 10]. Similar to UroA tumors 
in the Lund classification, the luminal-papillary subtype in TCGA and Consensus 
classification were also characterized by FGFR3 mutations; by papillary histology; 
and by low carcinoma-in-situ scores. Such cancers had a low risk for progression, 
and while preliminary data suggests a low likelihood of response to cisplatin-based 
NACT [25], they may respond to tyrosine kinase inhibitors of FGFR3 family [26, 27] 
or to PPARγ-inhibitors [10] or to Estrogen receptor modulators [28].
Genomically unstable subtype (GU) of luminal tumors expressed FOXM1 and 
absent to low levels of FGFR3, but not KRT5 [9]. They also frequently showed RB1 
loss, and had a high rate of TP53 mutations. Highest ERBB2 expression is also seen 
in GU subtype. Although they showed urothelial differentiation signature, GU 
tumors were in fact poorly differentiated and frequently high grade on histology 
[9, 10]. On immunohistochemistry, they did not express CK5, but expressed late cell 
cycle makers such as p16 [10]. The luminal unstable subtype of Consensus clas-
sification showed similar features to the GU subtype described by Lund University 
group. These tumors may respond to drugs targeting ERBB2 [23].
In terms of prognosis, luminal papillary tumors or UroA tumors had very good 
prognosis, while the GU subtype showed an intermediate prognosis compared to 
urothelial-like and basal/SCC-like tumors [10, 12, 16].
Modern Approach to Diagnosis and Treatment of Bladder Cancer
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4.1.2 Intrinsic non-luminal subtype: Basal and neuronal
Intrinsic non-luminal MIBC included basal MIBC (Choi et al., 2014) [13] and 
neuronal or small cell neuroendocrine MIBC. The basal subtype has been renamed 
basal-squamous in the later classification systems as it is characterized by squamous 
differentiation [8, 12].
Basal-squamous MIBCs expressed signal biomarkers similar to normal basal 
cells in the urothelium like high molecular weight cytokeratins KRT1, KRT5, KRT6, 
KRT14, KRT16, 15 KRT6A, KRT6B, KRT6C and CD44 and CDH3 [8, 11]. However, 
unlike normal basal urothelial cells which retained urothelial differentiation factors 
(GATA3 and PPARG), the basal-squamous subtype showed down-regulation of this 
signature. Interestingly, they had a higher incidence in females unlike all the other 
subtypes which were male predominant [11].
Basal MIBCs were also characterized by up-regulation of the epidermal growth 
factor receptor (EGFR) and other ligands of the epidermal differentiation complex 
such as S100A7 and SPRR1B, similar to basal breast and head and neck squamous 
cell carcinomas. Cell cycle regulator p63 played a central role in controlling 
the basal pathway of differentiation, and STAT3, NFκB, and Hypoxia Induced 
Factor-1α (HIF-1α) were also involved [23].
Without treatment, basal MIBCs had poorer survival [13, 14] but they 
responded well to neoadjuvant chemotherapy [11]. Because NACT pathological 
complete response is associated with excellent long-term survival, aggressive 
early management of basal MIBCs with NACT offers the best chance for improved 
survival for these patients.
This subtype also had the strongest immune expression signature, including T 
cell markers, inflammation genes and lymphocytic infiltrates. It is predicted that 
the basal-squamous subtype may respond to anti-PD-L1, anti-PD-1 and anti-
CTLA-4 agents [28, 29]. EGFR-, NFκB, HIF-1α/VEGF, and/or STAT3-targeted 
agents may also have a role within this subtype [27].
The neuronal subtype showed no histopathological distinction from other types 
of MIBC in most cases. Nonetheless, they had high levels of TP53 and RB1 muta-
tions, similar to small cell carcinomas in other tissues. It had the worst survival of 
the mRNA expression subtypes, making it important to recognize [10, 11].
4.1.3  Non-intrinsic subtypes: P53-like, luminal-infiltrated, stromal-like, 
infiltrated, claudin-low
P53-like MIBCs showed some overlap in gene expression with luminal and basal 
subtypes of the UNC classification but were characterized by the expression of an 
active wild-type p53-associated gene expression signature [13]. P53-like subtype 
of bladder cancer responded poorly to neo-adjuvant chemotherapy [13, 28, 30]. 
Wild-type p53-induced reversible senescence and quiescence had been implicated 
in causing chemo-resistance. However, even though p53-associated expression 
signatures were present, TP53 mutation frequencies were found to be similar in 
luminal, p53-like and basal subtypes defined by Choi et al., (2014). The p53-ness 
as measured by mRNA expression was found to be a more accurate predictor of 
de novo and induced MIBC chemo-resistance than analysis of TP53 mutational 
status [23].
The luminal-infiltrated subtype reported by the TCGA was characterized by low 
tumor purity, with high expression of epithelial-mesenchymal transition (EMT) 
and myofibroblast markers, and of the miR-200 s. It showed medium expression of 
PD-L1 and CTLA4 immune markers. This subtype had been reported to respond to 
immune checkpoint inhibitors like Anti-PD-L1 [29].
9
Molecular Classification of Bladder Cancer
DOI: http://dx.doi.org/10.5772/intechopen.97393
Stromal-like subtype from the Consensus classification, the infiltrated subtype 
from the Lund classification [10] and claudin-low subtype of the MD Anderson 
Cancer Centre classification [14] all showed similar features of low-tumor purity, 
high EMT and stromal related transcripts with increased cancer stem cell-like 
gene expression profile. Claudin-low tumors described by Damrauer et al. [14], 
in addition, showed increased expression of claudins-1, 3, and 7 and had a simi-
lar expression profile to the claudin-low breast cancer subtype. Dadhania et al., 
[24] in their meta-analysis of the TCGA, Lund and MD Anderson cohorts also 
identified a subset of tumors with low urothelial and basal expression signatures, 
which they termed “double negative”, which showed similar expression profile to 
 claudin-low tumors.
With tumor progression, alterations are seen both in the intrinsic characteristics 
of the tumor cell, as well as in the tumor microenvironment (TME). Early MIBC 
molecular classification systems mainly focused on the molecular classification of 
tumor cells themselves. With a deeper understanding of BC cells and their TME, 
molecular subtyping efforts have begun to focus more on intratumor heterogene-
ity, stromal-extracellular matrix (ECM) interactions and immune cell infiltration, 
allowing further refinement of the molecular subtypes. Currently, studies on 
molecular subtyping are mainly based on whole tumor DNA or RNA studies rather 
than focusing on a single tumor cell. In this method, intratumoral heterogene-
ity can greatly affect the accuracy of molecular subtyping. Warrick et al. [31] 
conducted a pathological examination on 309 bladder cancer markers and found 
that nearly one fourth of them exhibited intratumoral variation in tissue samples. 
Out of the 83 specimens subtyped by them with the Lund subtyping system, 39% 
exhibited molecular heterogeneity. Even among the subtypes, the basal-squamous 
subtype particularly showed the greatest variability; with approximately 78% of 
these tumors simultaneously exhibiting the genomically unstable or urothelial-like 
subtype.
Several immunohistochemistry based algorithms have been developed in an 
attempt to classify bladder cancer into clinically and prognostically significant 
molecular subtypes [9, 10, 24, 32]. The use of immunohistochemistry as a surrogate 
to molecular testing shows promise in making molecular subtyping amenable 
to widespread use. The use of a simple panel comprising of a luminal urothelial 
markers like GATA3 and basal keratin marker like KRT5 can help identify a GATA3 
positive, KRT5 low luminal subtype and a GATA3 negative, KRT5 high basal 
subtype. Tumors which are negative for GATA3 and have low keratin may be further 
tested for mesenchymal or neuroendocrine markers. The luminal tumors may also 
be further subtyped into uro-like tumors which are p16 negative and genomically 
unstable tumors which show p16 positivity [33]. The subtypes thus identified have 
demonstrated significant prognostic and predictive value [24, 32].
5. Clinical significance of molecular subtypes of bladder cancer
Not only do clinical outcomes differ among the molecular subtypes, but also 
therapeutic response. The gold-standard for management of MIBCs for disease 
confined to the pelvis includes radical cystectomy preceded by platinum based neo-
adjuvant chemotherapy. Although a significant minority of patients treated this way 
achieves durable response and improved cancer specific survival, a sizeable fraction 
does not respond. In fact, a meta-analysis has suggested that there is only 5% abso-
lute survival benefit at 5 years for patients treated in this manner [34]. In addition, 
concerns regarding delayed surgery and risk of serious morbidity have limited the 
usage rates of NACT for cystectomy patients at 25% or less [35, 36]. Biomarker tests 
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that predict chemo-response could address these problems by identifying patients 
most likely to benefit. In this regard, data suggests that NAC confers the greatest 
benefit in basal tumors [11, 29], while the “p53-like subtype” has been reported to 
confer chemo-resistance [13]. However, current ISUP working group guidelines of 
2020 do not recommend routine subtyping to guide NACT [37].
Data published by the TCGA Consortium stated that about 69% of BCs contain 
potentially actionable therapeutic targets which associate with specific molecular 
subtypes [11]. Mutations and amplifications of FGFR3 are seen in 50–80% of 
superficial bladder cancers and up to 20% of MIBCs [19]. Luminal-papillary tumors 
demonstrate a high rate of these alterations [11]; however, clinical trials have not 
yet incorporated molecular classification to determine patient eligibility. Similarly 
PIK3CA is also a frequently mutant gene and therapies targeting PI3K pathway have 
also shown preclinical BC trials [38]. Other targets such as ERBB2 and TSC1 are also 
being investigated as therapeutic targets.
Molecular subtyping may also provide a guide to BC immunotherapy. Anti-
programmed death 1 (PD-1) and anti-programmed death-ligand 1(PD-L1) and 
cytotoxic T-lymphocyte antigen 4 (CTLA-4) are important second line therapies 
for MIBC with NAC failure. A few are also approved as first line therapy for cispla-
tin ineligible cases. Unfortunately, not all patients benefit from immunotherapy 
[39, 40]. Testing for biomarkers of response involves IHC for PD-1 or PD-L1 or 
estimation of tumor mutation burden, micro-satellite instability or immune-
microenvironment of the tumor. However, none of these biomarkers have shown 
overwhelming predictive efficacy over others [41–43]. The luminal infiltrated 
subtype in the TCGA 2017 subtyping system was found to be enriched in PD-L1, 
CTLA-4 and other immune signatures. In particular, although this subtype did not 
respond well to NACT, they showed good response to anti-PD-L1 and anti-PD-1 
treatment. The basal subtype has also shown response to immunotherapeutic agents 
in addition to being sensitive to NACT [11, 29]. Molecular subtypes may thus help 
define patient selection for immunotherapy.
6. Conclusion
Compared to traditional classification of BCs, molecular subtypes provide 
more information regarding tumor biology, prognosis and treatment. In general, 
BC can be divided into luminal and non-luminal subtypes based on their degree 
of urothelial differentiation. The luminal subtype is further subdivided into those 
with papillary features, which are superficial, predominantly non-invasive. Though 
they carry good prognosis when compared to other treatment-naïve subtypes, they 
do not respond well to conventional NAC and may benefit from targeted therapies. 
The luminal infiltrated type has more inflammatory and stromal signatures. They 
are more invasive than luminal papillary tumors and may respond well to immuno-
therapies. Basal/squamous tumors express stem cell and squamous differentiation 
associated gene expression signatures. They are aggressive untreated, but respond 
well to NACT as well as immunotherapies but are insensitive to radiotherapy. The 
neural subtype forms a minority of non-luminal tumors with neuronal or neu-
roendocrine phenotype and usually carry poor prognosis but respond to NACT. 
There are an increasing number of molecular subtyping systems being constantly 
updated. While they carry great potential to reform BC prognostication and thera-
peutics, they are not entirely without limitations. Accessibility is a key issue in the 
present times. Molecular subtyping is mainly based on “static” research, especially 
in NMIBC, and enables a one-time detection and analysis of tumor specimens 
rather than “dynamic” tracking to over the disease course. It has also mainly focused 
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on genome and transcriptome research so far but proteomics and immune status of 
tumors are also closely related to their development. Therefore, the implementation 
of multiomics is a key necessity in future studies on molecular subtyping. Intra-
tumor heterogeneity also provides another challenge with patient outcome being 
dominated by one subtype more than the other. With the rapid development of 
single-cell high-throughput sequencing, mass spectrometric analysis, immune cell 
analysis and other technologies, the accuracy of the molecular subtyping prediction 
system need further improvement. Compared to the existing classification system, 
molecular subtyping methods offer a more comprehensive analysis, particularly to 
guide adjuvant chemotherapy, targeted therapy and immunotherapy. In the future, 
these classifications will become an important complementary approach to tradi-
tional pathological classification.
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